Granite Bay Wealth Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
– Sell
-22,520
Closed -$8K – 80
2023
Q1
$8K Buy
22,520
+3,400
+18% +$3.05K 0.01% 75
2022
Q4
$17K Sell
19,120
-700
-4% -$929 0.01% 66
2022
Q3
$31K Hold
19,820
– – 0.02% 57
2022
Q2
$40K Sell
19,820
-300
-1% -$519 0.03% 56
2022
Q1
$47K Buy
20,120
+3,850
+24% +$12K 0.04% 61
2021
Q4
$76K Buy
+16,270
New +$101K 0.08% 60

Other funds holding SRNE

Granite Bay Wealth Management's SRNE Position: Q2 2023 in Review

Granite Bay Wealth Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q2 2023, closing a stake of 22,520 shares — an estimated $8K sold.

Granite Bay Wealth Management first reported a position in SRNE in Q4 2021 and held it in 6 quarters. The position peaked at $76K in Q4 2021. 9 funds tracked by Wall St. Rank hold SRNE as of Q2 2023.

  • Granite Bay Wealth Management reported no remaining Sorrento Therapeutics, Inc. position as of Q2 2023 after selling out during the quarter.
  • Granite Bay Wealth Management sold 22,520 Sorrento Therapeutics, Inc. shares in Q2 2023, an estimated $8K.
  • Granite Bay Wealth Management first reported a position in Sorrento Therapeutics, Inc. in Q4 2021 and held it in 6 quarters.
  • Granite Bay Wealth Management's Sorrento Therapeutics, Inc. position peaked at $76K in Q4 2021.
  • 9 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2023.

Based on Granite Bay Wealth Management's 13F filing for Q2 2023, filed 19 Jul 2023.